BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits - 12/12/23

Abstract |
Background |
Risk-reducing mastectomy (RRM) is the most effective breast cancer risk-reduction strategy in BRCA1/2 mutation carriers. We examined factors associated with RRM and its relationship with overall survival (OS).
Methods |
Patients aged 18-80y at diagnosis of their BRCA1/2 mutation were selected from our institutional database and stratified by RRM receipt. Differences were tested; unadjusted OS was estimated.
Results |
Of the 306 patients, median age was 43y; median follow-up was 41.6mo. Patients undergoing RRM were more often married with a history of pregnancy (both p ≤ 0.05). Of female patients, 23.1% underwent RRM. Two patients had malignancy detected at RRM, and one developed breast cancer after RRM. Higher unadjusted OS was observed with RRM (p = 0.02).
Conclusions |
Our analyses suggest that family-structure may play a role in a patient's decision to undergo RRM. We also demonstrated RRM is likely associated with improved survival, potentially underscoring the importance of this option for BRCA1/2 mutation carriers.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Family structure factors were associated with undergoing risk reducing mastectomy. |
• | Mastectomy was less likely in those with cardiac/pulmonary and systemic comorbidities. |
• | Women with BRCA1 mutations were more likely to undergo mastectomy than BRCA2. |
• | Survival was improved with risk reducing mastectomy. |
Keywords : Breast cancer, BRCA, Risk-reducing, Prophylactic, Mastectomy, Genetics
Plan
Vol 227
P. 146-152 - janvier 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
